BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets as a spinout from BridgeBio Pharma, concentrating the parent firm's cancer-targeted therapy pipeline into a standalone entity. Operating within the biotechnology and oncology sector, BBOT filed a current report on Form 8-K with the Securities and Exchange Commission on September 8, 2026, under accession number 0001193125-26-385225, disclosing a material corporate development. The company continues to advance its oncology-focused programs as an independent publicly traded issuer. For complete filing details, corporate structure data, and real-time SPAC and de-SPAC intelligence on BBOT and hundreds of other transactions, sign up for full access at SpacDesk.